A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
for
Prostate Cancer, Prostatic Neoplasms
Location: Duarte CA, Irvine CA, La Jolla CA, Los Angeles CA,
Sponsor: Merck Sharp & Dohme LLC
Sex: Male
Age: 18+
Code: NCT06925737
Phase3, Recruiting
New
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate
for
Prostate Cancer (Adenocarcinoma),
Location: Boston MA
Sponsor: Prostate Cancer Clinical Trials Consortium
Sex: Male
Age: 18+
Code: NCT06844383
Phase2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
New
Circulating Tumor DNA in High Risk Localized Prostate Cancer
for
Prostate Cancer
Location: Pittsburgh PA
Sponsor: University of Pittsburgh
Sex: Male
Age: 18+
Code: NCT07222436
Recruiting
New
Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer
for
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Location: Salt Lake City UT
Sponsor: University of Utah
Sex: Male
Age: 18+
Code: NCT07216248
Phase2, Recruiting
New
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
for
Castration-Resistant Prostatic Cancer, Metastasis
Location: Washington D.C. DC, Germantown TN
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06863272
Phase1, Phase2, Recruiting
New
Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
for
Prostate Cancer (CRPC),
Location: Grand Rapids MI
Sponsor: ARTBIO Inc.
Sex: Male
Age: 18+
Code: NCT07214961
Phase1, Recruiting
New
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
for
Castration-Sensitive Prostate Carcinoma,
Location: Coeur d'Alene ID, Post Falls ID, Sandpoint ID,